Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
286 studies found for:    "Breast cancer male"
Show Display Options
RSS Create an RSS feed from your search for:
"Breast cancer male"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting An Observational Registry-Based Study of a Potential Link Between Finasteride (MK-0906) and Male Breast Cancer in 4 Nordic Countries (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention: Drug: Finasteride
2 Recruiting A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
4 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
5 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pineal Gland Astrocytoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Anaplastic Thyroid Cancer;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Cancer;   Extra-adrenal Paraganglioma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrinoma;   Glucagonoma;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Insular Thyroid Cancer;   Insulinoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Pancreatic Polypeptide Tumor;   Peripheral T-cell Lymphoma;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Tumor;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Islet Cell Carcinoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Small Intestine Lymphoma;   Somatostatinoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adult Soft Tissue Sarcoma;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Follicular Thyroid Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Rectal Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Colon Cancer;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Colon Cancer;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Rectal Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: romidepsin;   Other: pharmacological study
6 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Completed AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Renal Cell Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AFP464;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: tamoxifen citrate;   Drug: busulfan;   Drug: thiotepa;   Drug: melphalan;   Biological: aldesleukin;   Biological: sargramostim;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
9 Completed Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: tipifarnib;   Drug: capecitabine;   Drug: docetaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Completed Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: trastuzumab
11 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
13 Active, not recruiting Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: Central Nervous System Metastases;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Invasive Lobular Breast Carcinoma;   Invasive Lobular Breast Carcinoma With Predominant in Situ Component;   Liver Metastases;   Lobular Breast Carcinoma in Situ;   Lung Metastases;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tubular Ductal Breast Carcinoma;   Tumors Metastatic to Brain
Interventions: Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: stereotactic radiosurgery
14 Not yet recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine;   Other: laboratory biomarker analysis
15 Active, not recruiting
Has Results
Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: cixutumumab;   Drug: lapatinib ditosylate;   Drug: capecitabine
16 Withdrawn A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
Conditions: Central Nervous System Metastases;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
17 Recruiting Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: ganetespib;   Drug: paclitaxel;   Biological: trastuzumab
18 Withdrawn Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: external beam radiation therapy;   Other: questionnaire administration;   Procedure: therapeutic conventional surgery
19 Completed Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: becatecarin;   Other: laboratory biomarker analysis
20 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: pharmacological study;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years